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The pathogenic mechanisms of frontotemporal
dementia (FTD) remain poorly understood. Here we
generated multiple induced pluripotent stem cell
lines from a control subject, a patient with sporadic
FTD, and an FTD patient with a novel heterozygous
GRN mutation (progranulin [PGRN] S116X). In
neurons and microglia differentiated from PGRN
S116X induced pluripotent stem cells, the levels of
intracellular and secreted PGRN were reduced, es-
tablishing patient-specific cellular models of PGRN
haploinsufficiency. Through a systematic screen of
inducers of cellular stress, we found that PGRN
S116X neurons, but not sporadic FTD neurons, ex-
hibited increased sensitivity to staurosporine and
other kinase inhibitors. Moreover, the serine/threo-
nine kinase S6K2, a component of the phosphati-
dylinositol 3-kinase and mitogen-activated protein
kinase pathways, was specifically downregulated in
PGRN S116X neurons. Both increased sensitivity to
kinase inhibitors and reduced S6K2 were rescued
by PGRN expression. Our findings identify cell-
autonomous, reversible defects in patient neurons
with PGRN deficiency, and provide a compelling
model for studying PGRN-dependent pathogenic
mechanisms and testing potential therapies.INTRODUCTION
Frontotemporal dementia (FTD), the second most common form
of presenile dementia before the age of 65, is associated withCfocal atrophy of the frontal or temporal lobes and deficits in
cognition, behavior, and language (Boxer and Miller, 2005).
Mutations that cause FTD have been identified in several
genes, including those encoding valosin-containing protein
(VCP; Watts et al., 2004), charged multivesicular body protein
2B (CHMP2B; Skibinski et al., 2005), progranulin (PGRN; Baker
et al., 2006; Cruts et al., 2006), and chromosome 9 open reading
frame 72 (C9ORF72; DeJesus-Hernandez et al., 2011; Renton
et al., 2011). It is not known how these diverse mutations cause
similar clinical manifestations, and no effective treatment is
available.
The secreted glycoprotein PGRN has been implicated in cell
growth and survival, inflammation, synaptic functions, and other
cellular functions (He and Bateman, 2003; Yin et al., 2010; Tapia
et al., 2011). Although most (if not all) pathogenic mutations
in GRN lead to pathological changes in FTD due to PGRN hap-
loinsufficiency (Baker et al., 2006; Cruts et al., 2006), the under-
lying molecular mechanism is unknown. PGRN mutations are a
common cause of FTD. However, no robust pathological pheno-
type has been found in Grn+/– mice, and selective neuronal cell
loss is limited even in Grn knockout mice (Ahmed et al., 2010;
Ghoshal et al., 2012; Petkau et al., 2012; Yin et al., 2010).
Thus, amore suitablemodel for dissecting the pathogenicmech-
anisms that underlie PGRN haploinsufficiency is needed.
The ability to generate human induced pluripotent stem cells
(iPSCs) offers an unprecedented opportunity to analyze the
molecular consequences of pathogenic mutations in the context
of the unique genetic background of individual patients (Yama-
naka, 2007). Indeed, iPSCs have been generated from patients
with different neurodegenerative diseases (e.g., Dimos et al.,
2008; Ebert et al., 2009; Soldner et al., 2009; Nguyen et al.,
2011; Israel et al., 2012). In this study, we generated multiple
FTD-patient-specific iPSC lines and established a human neu-
ronal model of PGRN haploinsufficiency. From studies of
human postmitotic neurons derived from these lines, we identifyell Reports 2, 789–798, October 25, 2012 ª2012 The Authors 789
Figure 1. Generation and Characterization of FTD Patient-Specific iPSCs
(A–C) Total and endogenous (Endo) levels of the reprogramming factors in control, sporadic, and PGRNS116X iPSC lines relative to the values in H9, as assessed
by qRT-PCR. Values are mean ± SEM.
(D) Genomic DNA sequencing of the heterozygous PGRN S116X mutation g.4627C > A (p.S116X: nonsense mutation) in PGRN S116X iPSCs.
(E) Methylation status of the OCT4 promoter for control iPSC line 20, sporadic iPSC line 9, and PGRN S116X iPSC line 26.B, unmethylated CpG dinucleotides;
C, methylated CpG dinucleotides.
(F) Immunofluorescence analysis of pluripotencymarkers in control iPSC line 20, sporadic iPSC line 9, and PGRNS116X iPSC line 26, and their respective normal
karyotypes. Cell nuclei were counterstained with DAPI (blue). Scale bar, 50 mm.
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cell-autonomous and reversible defects in specific signaling
pathways that are compromised in PGRN-deficient neurons.
RESULTS
Generation and Characterization of FTD-Patient-
Specific iPSCs
The two FTD patients under investigation in this study were part
of a longitudinal dementia research program at the Memory and
Aging Center, University of California, San Francisco. Both had
an 8-year history of behavioral changes andmemory impairment
at the time of tissue collection for this study. One patient, a 67-
year-old male with sporadic FTD, tested negative for mutations
in GRN, MAPT, and C9ORF72. The other patient, a 64-year-old
male with a significant family history of dementia, had behavioral
variant FTD. MRI in this patient demonstrated severe bifrontal
and temporal atrophy associated with gliosis in the frontal lobes
(greater on the right). One year later, MRI scans showed progres-
sion of atrophy and gliosis. Genetic testing revealed a novel
nonsense mutation in GRN, p.S116X (g.4627C > A, c.347C > A),
which is predicted to result in a premature stop codon. Both
FTD patients had parkinsonism, which is typical of all FTD
patients with PGRN mutations. An age-matched subject, a clini-
cally normal 64-year-old male with no mutations in GRN,MAPT,
or C9ORF72, served as a control.
Skin biopsies from the upper right thigh were obtained from
all three subjects, and primary fibroblasts were derived. After
expansion, the fibroblasts were reprogrammed with four tran-
scription factors (OCT3/4, SOX2, KLF4, and CMYC) into putative
pluripotent stem cells as previously described (Takahashi et al.,
2007). Approximately 5 weeks after viral transduction, >50 iPSC
colonies per subject were selected on the basis of their embry-
onic stem cell (ESC)-like morphology and expanded further on
feeder cells.
To identify lines in which the exogenous reprogramming fac-
tors were completely silenced, we characterized 10–15 putative
iPSC lines from each subject by quantitative RT-PCR (qRT-
PCR). Complete transgene silencing was achieved when the
total expression of each reprogramming factor did not differ
from that of the endogenous gene (Figures 1A–1C). This assay
allows us to detect transgene expression levels of at least
20-fold above than the endogenous levels in ESC H9 cells.
Based on this analysis, we selected three lines per subject for
further characterization: control lines 16, 17, and 20 (Figure 1A);
sporadic FTD lines 9, 12, and 23 (Figure 1B); and PGRN S116X
lines 1, 14, and 26 (Figure 1C). The total expression of each re-
programming factor was not different from that of the endoge-
nous gene (Figures 1A–1C), indicating complete transgene
silencing. All lines expressed marker genes of undifferentiated
ESCs, such as OCT3/4, SOX2, and NANOG, at levels compa-
rable to those in ESC line H9. Two additional stem cell markers,
teratocarcinoma-derived growth factor 1 (TDGF1, or CRIPTO)(G) In vitro (EB formation) and in vivo (teratoma formation) differentiation of control
three germ layers. For in vitro studies, cells were immunostained with a-fetopro
(nuclei). Hematoxylin/eosin staining of teratoma sections showed neuron/rosett
Scale bar, 50 mm.
See also Figure S1.
Cand zinc finger protein 42 (ZFP42, or Rex1), were also expressed
at levels equivalent to those in H9 cells (Figure S1A).
Sequencing confirmed that the PGRN S116X iPSC lines re-
tained the GRN nonsense mutation (g.4627C > A, c.347C > A;
Figure 1D). Analysis of the OCT4 promoter region showed that
undifferentiated iPSCs were hypomethylated relative to the
respective fibroblasts from which they were derived (Figure 1E).
In addition, iPSCs expressed the stem-cell-specific surface
proteins SSEA4, TRA-1-60, TRA-1-81, NANOG, and OCT4, as
shown by immunostaining (Figures 1F and S1B). All nine iPSC
lines maintained a normal karyotype after reprogramming (Fig-
ures 1F and S1C) and could spontaneously differentiate into
cell types of all three germ layers in vitro (Figures 1G and S1C).
Moreover, representative iPSC lines from the subjects (control
line 20, sporadic line 9, and PGRN S116X line 26) transplanted
into severe combined immunodeficiency (SCID) mice gave rise
to teratomas in vivo (Figure 1G). These findings confirm the
successful reprogramming and generation of FTD-patient-
specific iPSC lines, and demonstrate that these lines are similar
to those in controls in terms of both their expression of stem cell
markers and their pluripotency.
Differentiation of FTD-Patient-Specific iPSCs into
Neurons
Next, we differentiated three fully reprogrammed iPSC lines at
passages 20–26 from each subject into postmitotic neurons,
using a protocol available in our lab (Delaloy et al., 2010). The
differentiation starts with neural induction, which is followed by
expansion of the neural progenitor cells and neural maturation.
The first step, induction of multilineage differentiation and em-
bryoid body (EB) formation, was inefficient when iPSCs were
maintained on feeder cells. Adaptation of iPSCs to feeder-free
conditions allowed robust and reliable formation of EBs (Figures
2A and 2B). After 5–6 days in suspension, neural induction was
initiated with basic fibroblast growth factor and N2 supplement,
and rosettes (elongated cells arranged in circular structures) ap-
peared (Figure 2C). Ten days later, the rosettes were isolated,
expanded in suspension as neurospheres for 3–4 weeks (Fig-
ure 2D), and dissociated into single cells. Terminal differentia-
tion was induced with glial-cell-line-derived neurotrophic factor,
brain-derived neurotrophic factor, ascorbic acid, and cyclic
AMP. Two weeks later, the cells displayed typical neuronal
morphology (Figure 2F). Both FTD and control iPSCs differenti-
ated at similar rates.
We then sought to determine whether the disease and/or
the mutation affected the percentage of neurons obtained with
this protocol. After 2 weeks, 80% of cells in culture were posi-
tive for the neuronal marker microtubule-associated protein 2
(MAP2) and had neuronal morphology (Figure 2G), and <4% of
cells were positive for the glial marker glial fibrillary acidic pro-
tein, regardless of the genetic mutation of the iPSC line used
(Figures 2G and 2K). Thus, the PGRN S116X mutation did notiPSC line 20, sporadic iPSC line 9, and PGRNS116X iPSC line 26 into cells of all
tein (AFP, endoderm), desmin (mesoderm), bIII-tubulin (ectoderm), and DAPI
e structures (ectoderm), smooth muscle (mesoderm), and ducts (endoderm).
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Figure 2. Differentiation and Characterization of Human Postmitotic Neurons Derived from FTD and Control iPSCs
(A–E) Phase-contrast images of the cells at different stages of neuronal differentiation. Scale bar, 100 mm.
(F) Representative images of 2-week-old cells stained with MAP2. Nuclear staining is shown in blue.
(G and K) Cells positive for MAP2 and GFAP as a percentage of all cells in 2-week-old cultures.
(H–J) Cells positive for VGLUT1, GABA, and TH (glutamatergic, GABAergic, and dopaminergic markers, respectively) as a percentage of MAP+ cells. On average,
200 cells were analyzed per experiment in (G)–(K) (n = 3 independent cultures). Values are mean ± SEM.
(L) Electrophysiological properties of control neurons and PGRN S116X neurons. Representative action potentials responding to step depolarization by current
injection from 0 pA to 400 pA (100 pA step) that could be blocked by tetrodotoxin (n = 24 for each line).
(M) Sample traces of mEPSCs from control (blue) and PGRN S116X (black) neurons. All neurons (n = 10 for each line) displayed synaptic responses and were
abolished by the AMPA receptor antagonist NBQX.
(N) Averaged mEPSC traces from control (blue) and PGRN S116X (black) neurons.
See also Figure S2.affect the percentage of neurons generated with the differen-
tiation protocol. Approximately 40% of the MAP2+ cells were
presumably glutamatergic and expressed VGLUT1 (Figure 2H),
and <10% of cells were GABA+ inhibitory neurons or tyrosine
hydroxylase (TH)+ dopaminergic neurons (Figures 2I and 2J).
Again, the percentages of neurons differentiated from control
and FTD-patient-specific iPSC lines were indistinguishable.
Additional analysis at the messenger RNA (mRNA) level in-792 Cell Reports 2, 789–798, October 25, 2012 ª2012 The Authorsdicative of glutamatergic (VGLUT1), GABAergic (GAD67) and
dopaminergic (TH) neuronal subtypes or postsynaptic density
(PSD95) detected no significant differences across the different
lines (Figures S2A–S2D). Thus, the PGRN S116X mutation did
not affect neural differentiation of iPSCs into specific type of
neurons.
We next performed whole-cell voltage-clamp recordings and
measured membrane properties and synaptic transmission on
Figure 3. FTD Patient-Specific Neuronal Model of PGRN Haploinsufficiency
(A) GRN mRNA expression levels in fibroblasts.
(B and D)GRNmRNAexpression levels in iPSC lines derived from control, sporadic, and PGRNS116X subjects (B) and neurons differentiated from iPSCs (D). The
values from control (fibroblasts) or control line 20 were set to one (n = 3–4 independent cultures).
(C and E) Amount of PGRN secreted into the medium over 24 hr by iPSCs (C) and iPSC-derived neurons (E). Values of control line 20 were set to 100% (n = 3–4
independent cultures).
(F) Intracellular PGRN levels in iPSC-derived neurons after medium collection. Values of control line 20 were set to 100% (n = 3–4 independent cultures).
Values in (A)–(F) are mean ± SEM. ***p < 0.001; patient cells were compared with control cells. See also Figure S3.neurons differentiated from two iPSC lines (control line 20 and
PGRN S116X line 26; Figures 2L–2N). Most cells in culture
were capable of inducing tetrodotoxin-sensitive action poten-
tials (control: 79.2%; PGRN S116X: 75%), which is consistent
with the finding that 80% of cells are MAP2-positive neurons
(Figure 2G). The resting membrane potential between two cell
lines does not show a statistically significant difference (control
neurons: 62.5 ± 1.5 mV; PGRN S116X: 60.0 ± 1.9 mV; n =
24, p = 0.17). To address whether these cells can form functional
synaptic connections, we found that PSD95 puncta were
present on dendrites of these neurons (Figure S2E), and also
measured AMPA-type glutamate receptor-mediated miniature
excitatory postsynaptic currents (mEPSCs). Neurons differenti-
ated from PGRN S116X iPSCs showed synaptic connections
indistinguishable from those of control neurons (mEPSC ampli-
tude of control neurons: 12.1 ± 1.7 pA, PGRN S116X: 14.37 ±
1.7 pA, p = 0.36; frequency of control neurons: 3.2 ± 0.6 pA,
PGRN S116X: 2.2 ± 0.2 pA, n = 10, p = 0.12). These results indi-
cate that postmitotic neurons differentiated from control and
PGRN S116X iPSCs are functional.
A Human Neuronal Model of PGRN Haploinsufficiency
To establish a human neuronal model of PGRN haploinsuffi-
ciency, we first examined the expression levels of PGRN in fibro-
blasts from each subject by qRT-PCR. GRN mRNA levels wereCsimilar in cells from the control subject and sporadic FTD patient
(Figure 3A), but in cells from the FTD patient with the PGRN
S116X mutation, the mRNA level was only 30% of that found
in the control (Figure 3A). This observation is consistent with
the substantially lower average plasma PGRN levels in FTD
patients harboring GRNmutations compared with those without
such mutations (Coppola et al., 2008; Finch et al., 2009).
However, after reprogramming, the GRNmRNA was 50% lower
in all three PGRN S116X iPSC lines (Figure 3B), as expected.
Moreover, the relative expression levels of GRN mRNA in all
control or sporadic FTD iPSCs showed little variation (Figure 3B).
Correspondingly, PGRN S116X iPSCs secreted 50% less PGRN
than iPSCs from the control subject and sporadic FTD patient
(Figure 3C).
Upon differentiation, GRN mRNA levels were 41% lower in
PGRN S116X neurons than in control and sporadic FTD neurons
differentiated from multiple iPSC lines (Figure 3D). The levels of
both intracellular and secreted PGRN in these neurons were
also correspondingly reduced, as measured by ELISA (Figures
3E and 3F). Thus, we established a patient-specific human
neuronal model of PGRN haploinsufficiency. We were also able
to differentiate these iPSCs into microglia as shown by expres-
sion of the microglia-specific marker Iba1 (Figures S3A and
S3B). PGRN secretion from these cells was also 50% lower
than in control and sporadic FTD cells (Figures S3C and S3D).ell Reports 2, 789–798, October 25, 2012 ª2012 The Authors 793
PGRN S116X Neurons Are More Sensitive to Cellular
Stress Induced by Inhibitors of the Phosphatidylinositol
3-Kinase/Akt and MEK/Mitogen-Activated Protein
Kinase Signaling Pathways
Compared with many other neurodegenerative diseases, the
cellular defects associated with FTD remain poorly defined.
Human neurons derived from patient-specific iPSCs are an
excellent system in which to examine disease-gene-specific
cellular phenotypes. To conduct such an examination, we first
used two iPSC lines from each patient and differentiated them
into postmitotic neurons. Under normal culture conditions,
PGRN S116X and control neurons show similar viability. As
a late-onset disease, FTD likely results from damage that accu-
mulates over time rather than from an acute effect of the reduced
PGRN levels. Very little is known about the cellular defects
caused by PGRN haploinsufficiency in human neurons. Thus,
to identify pathways that might be compromised in PGRN
S116X neurons, we performed a systematic screen with a variety
of inducers of cellular stress that affect different key cellular func-
tions/pathways, such as mitochondria, oxidative stress, endo-
plasmic reticulum (ER), proteasome, and cell survival. Neurons
derived from the healthy individual and the sporadic FTD patient
were used as controls.
We tested two well-known inducers of mitochondrial dysfunc-
tion, oligomycin (an ATP synthase inhibitor) and rotenone
(a complex I inhibitor), as well as a classical inducer of oxidative
stress (hydrogen peroxide). All three inducers of cell stress
reduced cell viability in a dose-dependent manner, and all geno-
types or disease states were equally affected (Figures S4A and
S4B; due to space limitations, data on oligomycin not shown).
In contrast, PGRN S116X neurons were more susceptible than
control neurons to ER stress induced by tunicamycin, an inhibitor
of protein N-glycosylation (Figure 4A), and proteasome activity
inhibition induced by lactacystin (Figure S4C). Because sporadic
FTD neurons also showed similar enhanced sensitivity to tunica-
mycin and lactacystin (Figures 4A and S4C), we concluded that
these cellular phenotypes are not specific to PGRN deficiency.
To further explore PGRN-dependent cellular defects in FTD
neurons, we also tested the effect of staurosporine, a broad-
spectrum kinase inhibitor that induces apoptosis (Figure 4B).
Interestingly, PGRN S116X neurons were more sensitive to
staurosporine than control or sporadic FTD neurons (Figure 4B).
This finding suggests that PGRN deficiency affects kinase path-
ways involved in cell survival, causing them to be more suscep-
tible to inhibition of such pathways.
To validate the findings of the cell viability assay, we also
measured the activation of caspase-3, a well-studied mediator
of apoptotic cell death. Consistent with the results of the cell
viability assay, PGRN S116X neurons showed greater cas-
pase-3 activation in response to staurosporine than control or
sporadic FTD neurons, whereas tunicamycin increased cas-
pase-3 activity in both PGRN S116X and sporadic FTD neurons
(Figure 4D). Because TDP-43 pathology is a hallmark in the
brains of FTD patients with PGRN deficiency (Neumann et al.,
2006), and increased caspase-3 activity leads to enhanced
cleavage and mislocalization of TDP-43 (Zhang et al., 2007),
we also analyzed the cellular distribution of TDP-43 under stress
to confirm our initial findings. After exposure to staurosporine,794 Cell Reports 2, 789–798, October 25, 2012 ª2012 The Authorsthe percentage of neurons with redistribution of TDP-43 from
the nucleus to the cytoplasm was significantly higher in PGRN
S116X neurons than in control or sporadic FTD neurons (Fig-
ure S4D). In contrast, tunicamycin resulted in similar increases
in the percentages of PGRN S116X and sporadic neurons with
cytoplasmic TDP-43. Interestingly, in the absence of a stress in-
ducer, the percentage of PGRNS116X neuronswith cytoplasmic
TDP-43 was higher than in control or sporadic FTD neurons (Fig-
ure S4D). Thus, both the caspase-3 and TDP-43 assays confirm
the intrinsic vulnerability of PGRN S116X neurons under stress.
Because staurosporine is a broad-spectrum kinase inhibitor
that affects several signaling pathways, we next tested more
specific kinase inhibitors to identify specific pathways affected
by reduced PGRN levels. PGRN S116X neurons were more
susceptible than control or sporadic FTD neurons to wortmannin
(Figure 4C) and LY294002 (data not shown), two phosphatidyli-
nositol 3-kinase (PI3K) inhibitors, and PD98059, anMEK inhibitor
(Figure S4E). These findings suggest that PGRN deficiency
impairs the PI3K/Akt and MEK/mitogen-activated protein kinase
(MAPK) signaling pathways in human neurons.
The Cellular and Molecular Defects of PGRN S116X
Neurons Can be Rescued by PGRN Expression
We next examined the causal relationship between PGRN
haploinsufficiency and enhanced sensitivity to cellular stress
induced by inhibitors of the PI3K/Akt and MEK/MAPK pathways
in PGRN S116X neurons. To that end, we used a CS-CW-GRN-
IG lentiviral vector to express PGRN in most (if not all) of the
human neurons in culture. The decreased cell viability (Figure 4E)
in staurosporine-treated PGRN S116X neurons was rescued by
PGRN expression. A similar result was obtained when increased
caspase-3 activation was used as the assay (Figure 4F), con-
firming the validity of the cell viability assay. In contrast, the
increased sensitivity of PGRN S116X neurons to the ER stress
induced by tunicamycin was not rescued by PGRN expres-
sion (Figure 4E). More importantly, the increased sensitivity of
PGRN S116X neurons to inhibitors of the PI3K/Akt and MEK/
MAPK pathways was also rescued (Figure 4E). Thus, the novel
cellular defects of PGRN S116X neurons uncovered under stress
are specific to PGRN deficiency.
Next, we sought to identify misregulated components in the
PI3K/Akt andMEK/MAPK pathways by performing gene expres-
sion analyses on two to three replicate neuron cultures differen-
tiated from each iPSC line and four iPSC lines per individual
(30 samples total). We compared PGRN S116X neurons and
sporadic FTD neurons versus control neurons, and identified a
number of differentially expressed genes, both shared between
PGRN S116X and sporadic FTD neurons, and specific to
PGRN S116X neurons (Figure 4G). In addition, a clustering anal-
ysis showed that the gene expression patterns in neurons differ-
entiated from three separate iPSC lines of the same individual
were remarkably similar to each other (Figure 4G).
Among the top downregulated genes in PGRN S116X neurons
(but not in control or sporadic FTD neurons) was the ribosomal
protein S6 kinase beta-2 (RPS6KB2; Figure 4H). This gene en-
codes S6K2, a member of the S6 kinase family of serine/threo-
nine kinases that has been shown to play an important role in
both the PI3K/Akt and MEK/MAPK signaling pathways (Fenton
Figure 4. Novel Cellular and Molecular Defects of PGRN S116X Neurons Can Be Rescued by PGRN Expression
(A–C) Effects of stress inducers on human neurons. Values are expressed as a percentage of the cells exposed to DMSO (control; n = 3–4 independent cultures).
(D) Caspase-3-like activity after exposure to 10 nM staurosporine, 0.5 mM tunicamycin, or DMSO for 24 hr.
(E and F) Measurement of cell viability (E) and caspase-3 activation (F) after rescue with PGRN expression (n = 5–6 independent cultures).
(G) Heat map depicting fold changes of gene expression in two to three neuron cultures differentiated from each one of the four iPSC lines from the sporadic FTD
patient (blue) or the PGRN S116X patient (fucsia) compared with control neurons.
(H) Gene expression changes on the array for GRN and RPS6KB2. The log fold change is relative to control neurons.
(I and J) PGRN expression restores S6K2 protein levels in PGRN S116X neurons.
(I) Representative western blotting image for S6K2 (control line 17 and PGRN S116X line 1).
(J) Quantification of S6K2 relative to GAPDH for three experiments performed on lines 17 and 20 (control), and lines 1 and 26 (PGRN S116X).
In all panels, values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
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and Gout, 2011), and is part of a coordinated network of differen-
tially expressed genes, including GRN (Figure S4H). The down-
regulation of the RPS6KB2 gene was confirmed by qRT-PCR
(Figure S4F) and its mRNA could be restored to wild-type level
by PGRN expression (Figure S4G). More importantly, S6K2
protein level is reduced by 50% in PGRN S116X neurons,
which can be rescued to wild-type level by PGRN expression
(Figures 4I and 4J). Taken together, these studies reveal novel
cellular and molecular defects of PGRN S116X neurons in the
PI3K/Akt and MEK/MAPK signaling pathways, which can be
rescued by PGRN expression (Figure S4I).
DISCUSSION
PGRN haploinsufficiency is a major cause in FTD pathogenesis
(Baker et al., 2006; Cruts et al., 2006). The underlyingmechanism
remains poorly understood, in part due to the lack of suitable
model systems. Even in Grn knockout mice, neuronal cell loss
is limited, and mechanistic studies are further complicated by
the finding that PGRN levels may vary widely among patient
brains in the later stages of disease (Chen-Plotkin et al., 2010).
The iPSC-based human neuronal model of PGRN haploinsuffi-
ciency, as established in this report, provides a platform for
testing small molecules that can restore PGRN levels. It also
serves as a valuable and more physiologically relevant model
for elucidating the mechanisms of FTD.
FTD is an age-dependent neurodegenerative disease, and
some intrinsic vulnerabilities of human neurons are more likely
to manifest under stress conditions in culture. Indeed, this
approach has been used recently to recapitulate some key
features of major neurodegenerative diseases in human neurons
derived from patient-specific iPSCs (e.g., Nguyen et al., 2011).
However, in contrast to the well-studied Alzheimer disease and
Parkinson disease (PD), little is known about neuronal defects
in FTD patients that are caused by PGRN deficiency. Differential
sensitivity of neurons to a particular stressor in culture within
a short time window may reveal partially defective molecular
pathways relevant to FTD pathogenesis.
A previous work showed that PGRN deficiency leads to
molecular alterations in apoptotic pathways and Wnt sig-
naling (Rosen et al., 2011). Our data here show that PGRN
S116X human neurons are more prone to reduced cell viability
induced by specific protein kinase inhibitors, implicating the
PI3K/Akt and MEK/MAPK signaling pathways in the molecular
pathogenesis of FTD. This cellular defect is rescued by ectopic
expression of PGRN in human PGRN S116X neurons, consistent
with previous findings that PGRN promotes the survival of rodent
primary neurons (Van Damme et al., 2008; Ryan et al., 2009; Xu
et al., 2011) and activates the PI3K/Akt/S6K pathway in cancer
cells (Zanocco-Marani et al., 1999). We also found that S6K2,
a component in both PI3K/Akt and MEK/MAPK signaling path-
ways, is specifically downregulated in PGRN S116X neurons
as part of a coordinated gene network, and its expression level
can be restored to normal by ectopic PGRN expression. Interest-
ingly, our reanalysis of the gene expression data published by
Chen-Plotkin et al. (2008) revealed that RPS6KB2 mRNA is
downregulated by 40% in the frontal cortex, but not in the
hippocampus or cerebellum, of FTD patients with PGRN muta-796 Cell Reports 2, 789–798, October 25, 2012 ª2012 The Authorstions. Taken together, these findings reinforce the notion that
the PI3K/Akt and MEK/MAPK signaling pathways are compro-
mised in PGRN S116X neurons, and highlight the primary role
PGRN plays in promoting neuronal survival.
ER stress and mitochondrial impairment have both been
closely linked to neurodegenerative diseases (Matus et al.,
2011; Schon and Przedborski, 2011). Our finding that neither
PGRN S116X nor sporadic FTD neurons show enhanced sensi-
tivity to mitochondrial or oxidative stressors argues that these
pathways are unlikely to be affected by reduced PGRN levels
in cultured neurons. However, mitochondrial dysfunction and
oxidative stress may develop at later stages of disease progres-
sion in FTD patients.
On the other hand, both PGRN S116X and sporadic FTD
neurons are more susceptible to inducers of ER stress and inhib-
itors of proteasome function than control neurons. This cellular
defect appears to be PGRN-independent since PGRN expres-
sion levels are normal in sporadic FTD neurons. In accordance
with our findings, it was recently reported that ER stress and
unfolded protein response activation contribute to both sporadic
FTD and familial FTD caused by MAPT mutations (Nijholt et al.,
2012). Moreover, both Ab and increased levels of phosphory-
lated tau induce ER stress in Alzheimer disease (e.g., Hooze-
mans et al., 2009), as does the accumulation of misfolded a-syn-
uclein in PD (Colla et al., 2012). Therefore, altered ER stress
responses are likely to be a general feature in a variety of neuro-
degenerative diseases.
In summary, we have established neuronal models of human
PGRN deficiency and demonstrated specific and reversible
defects that affect the survival of these neurons. Our findings
suggest that chronic weakening of prosurvival signaling path-
ways may render neurons more sensitive to environmental
insults in FTD patients with PGRN deficiency. Thus, in addition
to strategies to increase PGRN levels, therapeutic approaches
that generally enhance neuronal survival through growth factor
signaling may be beneficial in slowing disease progression in
these patients.
EXPERIMENTAL PROCEDURES
Isolation of Primary Human Skin Fibroblasts and Generation of
iPSCs
This study was approved by the Institutional Review Board and Ethics
Committees of the University of California, San Francisco, and written
informed consent was obtained in all cases. The patient with the PGRN
S116X mutation followed the classic clinical progression for FTD and devel-
oped parkinsonism, as do all FTD patients with PGRN mutations, but he did
not show typical features of PD dementia. The patient with sporadic FTD
also showed parkinsonism. Skin biopsies were collected, cut into small pieces,
and placed on culture dishes to allow the fibroblasts to expand. The cells
were maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 1X nonessential amino acids, and penicillin/strepto-
mycin (100 U/ml). iPSCs were generated as described previously (Takahashi
et al., 2007). Please see Supplemental Information for more details.
qRT-PCR, Immunocytochemistry, Differentiation and
Characterization of iPSCs, and Electrophysiology
Most of the experiments involving qRT-PCR, immunocytochemistry, differen-
tiation and characterization of iPSCs, and electrophysiology were performed
as previously described (Delaloy et al., 2010) with minor adjustments. Please
see Supplemental Information for more details.
PGRN Measurements
Fresh culture medium was added to the cells 24 hr before collection. After
the medium was collected, the cells were washed once with phosphate-
buffered saline (PBS), lysed with NP-40 buffer, and subjected to three
freeze-thaw cycles. Both the culture medium and the cell lysates were centri-
fuged at 12,000 rpm at 4C for 10min to clear cellular debris. Cell lysate super-
natants were assayed for protein concentration with the BioRad reagent
assay. Total cell lysates and culturemediumwere diluted, and the PGRN levels
were determined with an ELISA kit (Alexis Biochemicals, San Diego, CA) ac-
cording to the manufacturer’s instructions. Data were normalized to protein
concentration.
Stress-Induced Toxicity Assay
Two-week-old neurons were exposed for 24 hr to the following stress
inducers: tunicamycin, lactacystin, rotenone, oligomycin, hydrogen peroxide,
staurosporine, wortmannin, LY294002, PD98059, or DMSO. Cell viability was
determined with the WST1 cell-proliferation assay (Roche Applied Science,
Penzberg, Germany) according to the manufacturer’s instructions. Caspase-
3 activity assay is described in the Supplemental Information.
PGRN Rescue Experiments
HumanGRN (NM_002087.2) was inserted into a CS-CGW lentiviral vector with
Nhe I and Xho I. The vector also expressed green fluorescent protein through
an internal ribosome entry site. One-week-old neurons were transduced over-
night with lentivirus expressing PGRN or empty vector. The next morning, the
medium was doubled and thereafter replaced every other day. One week after
transduction, the neurons were exposed to 10 nM staurosporine, 0.5 mM tuni-
camycin, 50 mM PD98059, 75 nM wortmannin, or DMSO for 24 hr. Cells were
assayed for cell viability, caspase-3 activation, and S6K2 levels. A multiplicity
of infection of 50 was used in all cases.
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